Polarean touts recent xenon MRI research

MRI contrast agent developer Polarean is highlighting upcoming poster presentations at the American Thoracic Society’s (ATS) 2024 Respiratory Innovation Summit (RIS) May 17-18 in San Diego.

Nearly 18 months after the company's approval of Xenoview (xenon, Xe-129 hyperpolarized) for oral inhalation during MRI, Polarean's research includes 33 presentations from 10 different sites and multiple categories such as asthma, bronchopulmonary dysplasia, COPD, COVID-19, cystic fibrosis, hematopoietic stem cell transplant, lung cancer resection, radiation-induced lung injury, pulmonary arterial hypertension, and thoracic insufficiency syndrome, according to the vendor.

Xenoview is currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications, according to a statement on Polarean's website.

Featured presentations at the ATS summit include addressing healthy aging variations in ventilation from childhood to older age using xenon MRI, 4D hyperpolarized gas imaging of ventilation and dissolved gas biomarkers in COPD, quantifying the impact of cannabis smoking in the lungs of young adults, predicting changes in lung function in patients with idiopathic pulmonary fibrosis, and prospective multicenter results from the Transpire study, the company said.

Page 1 of 198
Next Page